© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Azitra, Inc. (AZTR) stock surged +16.40%, trading at $0.21 on AMEX, up from the previous close of $0.18. The stock opened at $0.32, fluctuating between $0.20 and $0.33 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 16, 2026 | 0.21 | 0.21 | 0.18 | 0.18 | 840.94K |
| Jun 15, 2026 | 0.21 | 0.22 | 0.20 | 0.20 | 724.69K |
| Jun 12, 2026 | 0.22 | 0.22 | 0.21 | 0.21 | 211.35K |
| Jun 11, 2026 | 0.23 | 0.23 | 0.21 | 0.22 | 189.33K |
| Jun 10, 2026 | 0.21 | 0.24 | 0.21 | 0.24 | 501.51K |
| Jun 09, 2026 | 0.20 | 0.21 | 0.20 | 0.21 | 363.01K |
| Jun 08, 2026 | 0.20 | 0.21 | 0.19 | 0.20 | 357.61K |
| Jun 05, 2026 | 0.21 | 0.22 | 0.21 | 0.21 | 127.1K |
| Jun 04, 2026 | 0.22 | 0.23 | 0.21 | 0.22 | 198.24K |
| Jun 03, 2026 | 0.22 | 0.23 | 0.21 | 0.22 | 264.74K |
| Jun 01, 2026 | 0.23 | 0.24 | 0.22 | 0.22 | 415.55K |
| May 29, 2026 | 0.21 | 0.24 | 0.21 | 0.23 | 1.36M |
| May 28, 2026 | 0.21 | 0.22 | 0.20 | 0.21 | 407.99K |
| May 27, 2026 | 0.21 | 0.21 | 0.20 | 0.21 | 518.24K |
| May 26, 2026 | 0.20 | 0.21 | 0.20 | 0.21 | 319.38K |
| May 22, 2026 | 0.21 | 0.22 | 0.20 | 0.20 | 534.6K |
| May 21, 2026 | 0.20 | 0.22 | 0.20 | 0.21 | 685.74K |
| May 20, 2026 | 0.19 | 0.20 | 0.18 | 0.20 | 663.23K |
| May 19, 2026 | 0.19 | 0.19 | 0.18 | 0.19 | 401.1K |
| May 18, 2026 | 0.19 | 0.19 | 0.18 | 0.19 | 611.17K |
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
| Employees | 12 |
| Beta | -1.5 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 9.93% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |